Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.60 |
| ▸ | MAOA | P21397 | 8/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284712 | 0.90 | ENPP2 (0.54) | MAOBMAOA | |
| SCHEMBL3507030 | 0.87 | MAOA (0.51) | MAOBMAOA | |
| SCHEMBL30679646 | 0.85 | CCR5 (0.65) | — | |
| SCHEMBL27868283 | 0.85 | MAOB (0.61) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL2288692 | 0.85 | SLC6A4 (0.53) | MAOBMAOA | |
| SCHEMBL2284584 | 0.85 | CCR5 (0.65) | — | |
| SCHEMBL7150750 | 0.84 | TUBB1 (0.55) | MAOBMAOANR4A2TUBB1 | |
| SCHEMBL7398748 | 0.84 | ENPP2 (0.61) | MAOBMAOA | |
| SCHEMBL3615463 | 0.84 | MAOB (0.58) | MAOBMAOATUBB1 | |
| SCHEMBL31591485 | 0.83 | MAOB (0.57) | MAOBMAOARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | MAOB 3505/4885MAOA 3492/4885RXRA 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.